company background image
GLTO

GalectoNasdaqGS:GLTO Stock Report

Market Cap

US$97.3m

7D

-4.5%

1Y

n/a

Updated

25 Sep, 2021

Data

Company Financials +
GLTO fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

GLTO Overview

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases.

Price History & Performance

Summary of all time highs, changes and price drops for Galecto
Historical stock prices
Current Share PriceUS$3.85
52 Week HighUS$3.80
52 Week LowUS$17.99
Beta0
1 Month Change-10.05%
3 Month Change-26.67%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-74.33%

Recent News & Updates

Shareholder Returns

GLTOUS BiotechsUS Market
7D-4.5%-2.3%0.1%
1Yn/a26.0%35.3%

Return vs Industry: Insufficient data to determine how GLTO performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how GLTO performed against the US Market.

Price Volatility

Is GLTO's price volatile compared to industry and market?
GLTO volatility
GLTO Beta0
Industry Beta1.03
Market Beta1

Stable Share Price: GLTO is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: GLTO's weekly volatility has decreased from 12% to 6% over the past year.

About the Company

FoundedEmployeesCEOWebsite
201128Hans Schambyehttps://galecto.com

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company’s lead product candidate is GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung. Its products also comprise GB2064, which is in Phase I/IIa for the treatment of myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase I/IIa for the treatment of cancer and fibrosis.

Galecto Fundamentals Summary

How do Galecto's earnings and revenue compare to its market cap?
GLTO fundamental statistics
Market CapUS$97.26m
Earnings (TTM)-US$48.87m
Revenue (TTM)n/a

0x

P/S Ratio

-2.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
GLTO income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
ExpensesUS$48.88m
Earnings-US$48.87m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-1.93
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did GLTO perform over the long term?

See historical performance and comparison

Valuation

Is Galecto undervalued compared to its fair value and its price relative to the market?

0.69x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate GLTO's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate GLTO's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: GLTO is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: GLTO is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate GLTO's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: GLTO is good value based on its PB Ratio (0.7x) compared to the US Biotechs industry average (3.3x).


Future Growth

How is Galecto forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

-32.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: GLTO is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: GLTO is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: GLTO is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: GLTO is forecast to have no revenue next year.

High Growth Revenue: GLTO is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: GLTO is forecast to be unprofitable in 3 years.


Past Performance

How has Galecto performed over the past 5 years?

-13.8%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: GLTO is currently unprofitable.

Growing Profit Margin: GLTO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if GLTO's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare GLTO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: GLTO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).


Return on Equity

High ROE: GLTO has a negative Return on Equity (-34.56%), as it is currently unprofitable.


Financial Health

How is Galecto's financial position?


Financial Position Analysis

Short Term Liabilities: GLTO's short term assets ($107.7M) exceed its short term liabilities ($4.8M).

Long Term Liabilities: GLTO's short term assets ($107.7M) exceed its long term liabilities ($635.0K).


Debt to Equity History and Analysis

Debt Level: GLTO is debt free.

Reducing Debt: GLTO had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: GLTO has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: GLTO has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 48.3% each year.


Dividend

What is Galecto current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate GLTO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate GLTO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if GLTO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if GLTO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of GLTO's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.6yrs

Average management tenure


CEO

Hans Schambye (55 yo)

1.67yrs

Tenure

US$3,903,539

Compensation

Dr. Hans T. Schambye, MD, Ph D, serves as Member of Board of Directors at BioInnovation Institute. Dr. Schambye is Co-Founder and has been Chief Executive Officer at Galecto, Inc. since 2020 and serves as...


CEO Compensation Analysis

Compensation vs Market: Hans's total compensation ($USD3.90M) is above average for companies of similar size in the US market ($USD548.69K).

Compensation vs Earnings: Hans's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: GLTO's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.


Board Members

Experienced Board: GLTO's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: GLTO insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: GLTO only recently listed within the past 12 months.


Top Shareholders

Company Information

Galecto, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Galecto, Inc.
  • Ticker: GLTO
  • Exchange: NasdaqGS
  • Founded: 2011
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$97.258m
  • Shares outstanding: 25.26m
  • Website: https://galecto.com

Number of Employees


Location

  • Galecto, Inc.
  • 75 State Street
  • Suite 100
  • Boston
  • Massachusetts
  • 2109
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/25 22:09
End of Day Share Price2021/09/24 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.